65 results match your criteria Cutaneous Manifestations of Smoking


Effects of tobacco and vaping on the skin.

Clin Dermatol 2021 Sep-Oct;39(5):762-771. Epub 2021 May 15.

Department of Dermatology, University of Connecticut School of Medicine, Farmington, Connecticut, USA; Department of Dermatology, University of Florida College of Medicine, Gainesville, Florida, USA. Electronic address:

Cigarette and electronic cigarette use are significant public health concerns across the United States. Tobacco use remains the single most preventable cause of morbidity and mortality in the world. Electronic cigarettes initially emerged as a better alternative to conventional cigarettes and for promoting smoking cessation; however, current evidence reveals similar deleterious health implications caused by both products on almost all organ systems, including the skin. Read More

View Article and Full-Text PDF
November 2021

Smoking associates with increased BAFF and decreased interferon-γ levels in patients with systemic lupus erythematosus.

Lupus Sci Med 2021 10;8(1)

Rheumatology Section, Medical School, University of Western Australia Faculty of Medicine, Dentistry and Health Sciences, Crawley, Western Australia, Australia.

Objective: In SLE, smoking increases the burden of cutaneous disease and organ damage, and leads to premature mortality. However, the effect of smoking on disease manifestations and cytokine levels of patients with SLE is unclear. This study compared characteristics of patients with SLE across smoking status, and determined the association of smoking with serum cytokine levels. Read More

View Article and Full-Text PDF
October 2021

Long-term effectiveness and drug survival of golimumab in patients affected by psoriatic arthritis with cutaneous involvement.

Clin Rheumatol 2022 Jan 19;41(1):75-84. Epub 2021 Aug 19.

Rheumatology Unit, Department of Medicine DIMED, University of Padova, Via Giustiniani 2, Padua, Italy.

Objectives: To determine the effectiveness of golimumab (GLM) in improving joint, periarticular structures and cutaneous manifestations in patients with moderate to severe psoriatic arthritis (PsA) with cutaneous psoriasis in different real-life clinical settings and 48-month drug survival.

Methods: Clinical and laboratory records were collected from PsA patients treated with GLM at baseline (T0) and after 6, 12, 24, 36, and 48 months of treatment. Comparisons were performed using a paired t-test or Wilcoxon test. Read More

View Article and Full-Text PDF
January 2022

Current systematic reviews and meta-analyses of COVID-19.

World J Virol 2021 Jul;10(4):182-208

Department of Internal Medicine, Icahn School of Medicine at Mount Sinai/NYC H&H Queens, New York, NY 11432, United States.

Background: Coronavirus disease 2019 (COVID-19) has left a significant impact on the world's health, economic and political systems; as of November 20, 2020, more than 57 million people have been infected worldwide, with over 1.3 million deaths. While the global spotlight is currently focused on combating this pandemic through means ranging from finding a treatment among existing therapeutic agents to inventing a vaccine that can aid in halting the further loss of life. Read More

View Article and Full-Text PDF

Smoking exposure in pack-years predicts cutaneous manifestations and damage in systemic lupus erythematosus.

Lupus 2021 Feb 24:961203321995257. Epub 2021 Feb 24.

Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

Objective: To examine the impact of cumulative smoking in pack-years on systemic lupus erythematosus (SLE) cutaneous manifestations and damage.

Methods: Our cohort study included 632 adult SLE patients at an academic center, meeting 1997 ACR or 2012 SLICC classification criteria. Outcomes were: (1) cutaneous SLICC Damage Index (SDI), (2) ACR and SLICC criteria. Read More

View Article and Full-Text PDF
February 2021

[Atypical actinomycosis revealed by distant dermatological disorders: Report of an unusual case and literature review].

Rev Med Interne 2021 Mar 7;42(3):210-213. Epub 2020 Dec 7.

Centre de soins dentaires, CHU de Rouen, 2, rue Guillaume-Lecointe, 76140 Le Petit-Quevilly, France.

Introduction: Dermatological manifestations of actinomycosis are classical, most often related to Actinomyces israelii. In most of the cases, they occur near to the primary focus, and in the cervicofacial area. Systemic dissemination with cutaneous distant metastasis is rare, most often related to A. Read More

View Article and Full-Text PDF

Characteristics of patients with systemic sclerosis suffering from a lower limb amputation: Results of a French collaborative study.

J Scleroderma Relat Disord 2020 Oct 27;5(3):224-230. Epub 2020 Apr 27.

Internal Medicine Department, Hôpital Nord, AP-HM, Marseille, France.

Objective: Systemic sclerosis mainly affects the microvascular network. However, macrovascular manifestations have been reported. We aimed to investigate the characteristics of systemic sclerosis patients with an amputation of a lower limb segment. Read More

View Article and Full-Text PDF
October 2020

Increased Mortality in Asians With Systemic Sclerosis in Northern California.

ACR Open Rheumatol 2020 Apr 21;2(4):197-206. Epub 2020 Mar 21.

Stanford University School of Medicine and Department of Veterans Affairs Palo Alto Health Care System, Palo Alto, California.

Objective: The objective of this study is to evaluate racial/ethnic differences in disease manifestations and survival in a US cohort of patients with systemic sclerosis (SSc), with a focus on Asian patients.

Methods: A retrospective cohort study was conducted among Kaiser Permanente Northern California adults with an incident SSc diagnosis by a rheumatologist from 2007 to 2016, confirmed by a chart review to fulfill 2013 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria. Self-reported race/ethnicity was categorized as non-Hispanic white, Asian, Hispanic, and black. Read More

View Article and Full-Text PDF

Prediction of Familial Hypercholesterolemia in Patients at High Atherosclerotic Cardiovascular Disease Risk Using a Recently Validated Algorithm.

CJC Open 2019 Jul 7;1(4):190-197. Epub 2019 Jun 7.

McMaster University, Hamilton, Ontario, Canada.

Background: The prevalence of heterozygous familial hypercholesterolemia (FH) is 1 of 250 in the general population and approximately 1 of 125 in patients with atherosclerotic cardiovascular disease (ASCVD), yet only a minority are diagnosed. The diagnostic criteria for FH rely on a point system using low-density lipoprotein cholesterol (LDL-C), family history, cutaneous manifestations, and molecular diagnosis. The aim of the present study was to determine the prevalence of FH in the elating vidence to chieve holesterol argets (REACT) registry. Read More

View Article and Full-Text PDF

Clinic experience in discoid lupus erythematosus: a retrospective study of 132 cases.

Postepy Dermatol Alergol 2019 Dec 21;36(6):739-743. Epub 2018 Aug 21.

Department of Dermatology, Faculty of Medicine, Van Yuzuncu Yil University, Van, Turkey.

Introduction: Lupus erythematosus (LE) is an autoimmune disease characterized by a broad range of cutaneous manifestations. Discoid LE (DLE) is the most common chronic manifestation of LE. Literature reviews show that there are a limited number of large-series studies investigating DLE. Read More

View Article and Full-Text PDF
December 2019

Tobacco smoking is an independent factor associated with retinal damage in systemic lupus erythematosus: a cross-sectional and retrospective study.

Rheumatol Int 2020 Mar 27;40(3):367-374. Epub 2019 Nov 27.

Rheumatology Service, Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas, GC, Spain.

To analyze the influence of tobacco smoking on systemic lupus erythematosus (SLE) clinical features and damage. Cross-sectional and retrospective, case-control study comparing SLE patients with and without tobacco exposure. Cumulative clinical data and comorbidities were collected, and severity (Katz index) and damage (SLICC/ACR damage index) (SDI) indices were calculated. Read More

View Article and Full-Text PDF

Management of cutaneous manifestations of lupus erythematosus: A systematic review.

Semin Arthritis Rheum 2020 02 12;50(1):95-127. Epub 2019 Aug 12.

Department of Rheumatology, St Vincent's Hospital, Melbourne, Australia; The University of Melbourne, Australia. Electronic address:

Background: Cutaneous lupus erythematosus (CLE), occurring with or without systemic lupus erythematosus (SLE), is a group of inflammatory skin diseases that can be very debilitating, causing significant psychological distress, and sometimes scarring.

Objectives: We sought to comprehensively present the evidence for different treatment modalities in patients with cutaneous manifestations of lupus erythematosus (LE).

Methods: Medline, Embase, Scopus and Cochrane CENTRAL were searched electronically from 1990 to March 2019, using keywords related to cutaneous lupus and synonyms and treatment. Read More

View Article and Full-Text PDF
February 2020

Impact of tobacco smoking upon disease risk, activity and therapeutic response in systemic lupus erythematosus: A systematic review and meta-analysis.

Autoimmun Rev 2019 Nov 11;18(11):102393. Epub 2019 Sep 11.

Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, Centre National de Référence des Maladies Systémiques Rares Est Sud-Ouest (RESO), Université de Strasbourg, F-67000 Strasbourg, France. Electronic address:

Systemic lupus erythematosus (SLE) is a complex disease with variable presentations, course and prognosis. Published studies present conflicting data regarding the impact of cigarette smoking on SLE risk, disease activity, clinical manifestations and treatment response. We performed a comprehensive literature search using Medline, EMBASE and the Cochrane Collaboration database, and hand searches of relevant bibliographies. Read More

View Article and Full-Text PDF
November 2019

Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study.

PLoS One 2019 25;14(1):e0210436. Epub 2019 Jan 25.

Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Background/aims: Extraintestinal cutaneous manifestations of IBD represent a severe disease complication and an early and accurate treatment might positively influence the disease course. Using the patient collective of the Swiss IBD Cohort Study (SIBDCS), we analysed epidemiological as well as clinical factors being associated with the onset of pyoderma gangrenosum, erythema nodosum and aphthous ulcers in IBD patients.

Methods: We included 3266 SIBDCs patients, 1840 with Crohn's disease (CD) and 1426 with ulcerative colitis (UC) or IBD unclassified (IBDU) and analysed the association of cutaneous manifestations with age, age at diagnosis time, type of disease, gender, family history, HLA-allotype, smoking, intestinal disease activity, therapy and other extraintestinal manifestations (EIM). Read More

View Article and Full-Text PDF
November 2019

Porphyria cutanea tarda and hepatoerythropoietic porphyria: Identification of 19 novel uroporphyrinogen III decarboxylase mutations.

Mol Genet Metab 2019 11 28;128(3):363-366. Epub 2018 Nov 28.

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address:

Porphyria Cutanea Tarda (PCT) is a cutaneous porphyria that results from the hepatic inhibition of the heme biosynthetic enzyme uroporphyrinogen decarboxylase (UROD), and can occur either in the absence or presence of an inherited heterozygous UROD mutation (PCT subtypes 1 and 2, respectively). A heterozygous UROD mutation causes half-normal levels of UROD activity systemically, which is a susceptibility factor but is not sufficient alone to cause type 2 PCT. In both Types 1 and 2 PCT, the cutaneous manifestations are precipitated by additional factors that lead to generation of an inhibitor that more profoundly reduces hepatic UROD activity. Read More

View Article and Full-Text PDF
November 2019

Smoking reduces the efficacy of belimumab in mucocutaneous lupus.

Expert Opin Biol Ther 2018 08 9;18(8):911-920. Epub 2018 Jul 9.

a Division of Rheumatology, Department of Medicine , Karolinska Institutet , Stockholm , Sweden.

Objectives: Recently, we demonstrated a negative impact of smoking on belimumab efficacy in patients with systemic lupus erythematosus (SLE). Here, we particularly investigated clinical effects of belimumab and a potential impact of smoking in mucocutaneous and articular SLE.

Methods: We surveyed 62 SLE patients treated between 2011 and 2017. Read More

View Article and Full-Text PDF

Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study.

Arthritis Rheumatol 2018 11 24;70(11):1829-1834. Epub 2018 Sep 24.

University Hospital Basel, Basel, Switzerland.

Objective: Data on the role of tobacco exposure in systemic sclerosis (SSc; scleroderma) severity and progression are scarce. We aimed to assess the effects of smoking on the evolution of pulmonary and skin manifestations, based on the European Scleroderma Trials and Research group database.

Methods: Adult SSc patients with data on smoking history and a 12-24-month follow-up visit were included. Read More

View Article and Full-Text PDF
November 2018

Disease severity and prophylactic measures in patients with cutaneous lupus erythematosus: results of a worldwide questionnaire-based study.

Postepy Dermatol Alergol 2018 Apr 24;35(2):192-198. Epub 2018 Apr 24.

Department of Dermatology, University of Rzeszow, Rzeszow, Poland.

Introduction: Due to a wide array of dermatologic manifestations, assessment of disease severity in cutaneous lupus erythematosus (CLE) remains challenging. Given a need for some standardization in this field, we conducted a worldwide questionnaire-based study among physicians experienced in CLE management.

Aim: We asked about CLE assessment, their prophylactic measures advised to patients, and treatment recommendations. Read More

View Article and Full-Text PDF

Cutaneous and Mucosal Manifestations of Sjögren's Syndrome.

Clin Rev Allergy Immunol 2017 Dec;53(3):357-370

Division of Rheumatology and Clinical Immunology, Humanitas Research Hospital, Via A. Manzoni 56, 20089 Rozzano, Milan, Italy.

Sjögren's syndrome is currently considered an "autoimmune epithelitis," as exocrine glands, especially salivary and lacrimal, are progressively destructed by an immune-mediated process associated with specific serum autoantibodies and local lymphocyte infiltrate. Xerostomia remains a key complain in patients with Sjögren's syndrome but should be evaluated also for other causes such as xerogenic medications, followed by radiation and chemotherapy for head and neck cancers, hormone disorders, infections, or other connective tissue diseases. Further, xerophtalmia (also known as dry eye) frequently associated with keratoconjunctivitis sicca cumulatively affects approximately 10-30% of the general population with increasing incidence with age and is more frequently secondary to non-autoimmune diseases. Read More

View Article and Full-Text PDF
December 2017

Generalized Discoid Lupus Erythematosus as the Presenting Sign of Small Cell Lung Carcinoma.

Skinmed 2017;15(3):218-220. Epub 2017 Jun 1.

Department of Dermatology, Mayo Clinic, Rochester, MN.

A 46-year-old woman with a 30 pack-year smoking history presented with a worsening eruption on the left cheek that failed to improve with metronidazole gel. The cutaneous eruption spread to most of her face and did not respond to a brief tapering course of prednisone. During the initial evaluation at our institution, approximately 6 weeks after the onset of the cutaneous eruption, the patient had erythematous, crusted plaques on her face and scalp (Figure 1A); they were also present on the V-area of the anterior aspect of the neck and upper region of the chest, the shoulders, and the arms, with isolated lesions on the trunk and legs. Read More

View Article and Full-Text PDF

Hepatic porphyria: A narrative review.

Indian J Gastroenterol 2016 Nov 31;35(6):405-418. Epub 2016 Oct 31.

Department of Internal Medicine, UAB University of Alabama in Birmingham, Birmingham, AL, USA.

Porphyrias are a group of metabolic disorders, which result from a specific abnormality in one of the eight enzymes of the heme biosynthetic pathway. These have been subdivided based on the predominant site of enzyme defect into hepatic and erythropoietic types and based on clinical presentation into acute neurovisceral and cutaneous blistering porphyrias. This review focuses on hepatic porphyrias, which include acute intermittent porphyria (AIP), variegate porphyria (VP), hereditary coproporphyria (HCP), aminolevulinic acid dehydratase deficiency porphyria (ADP), and porphyria cutanea tarda (PCT). Read More

View Article and Full-Text PDF
November 2016

The relationship between vascular biomarkers and disease characteristics in systemic sclerosis: elevated MCP-1 is predominantly associated with fibrotic manifestations.

Clin Exp Rheumatol 2016 Sep-Oct;34 Suppl 100(5):110-114. Epub 2016 Oct 14.

Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Turkey.

Objectives: To determine the relationship between vascular biomarkers reflecting the vascular injury and organ involvement in systemic sclerosis (SSc).

Methods: Seventy-two SSc patients (66 female) fulfilling 2013 ACR/EULAR Criteria were evaluated. Serum samples of patients were collected for flow-cytometric analysis of sCD40L, tPA, MCP-1, sE-selectin, IL-8, IL-6, VEGF, sP-selectin, TGF-β1 and VCAM levels (Bender MedSystems) in SSc patients and 20 healthy controls. Read More

View Article and Full-Text PDF
January 2017

Hydradenitis suppurativa and inflammatory bowel disease: An unusual, but existing association.

World J Gastroenterol 2016 May;22(20):4802-11

Mariabeatrice Principi, Antonella Contaldo, Andrea Iannone, Giuseppe Losurdo, Michele Barone, Enzo Ierardi, Alfredo Di Leo, Gastroenterology Section, Department of Emergency and Organ Transplantation, University of Bari, 70124 Bari, Italy.

Inflammatory bowel disease (IBD) could be associated with several extra-intestinal manifestations (EIMs) involving musculoskeletal, hepatopancreatobiliary, ocular, renal, and pulmonary systems, as well as the skin. In the last years, hidradenitis suppurativa (HS) is acquiring an increasing interest. IBD, especially Crohn's disease (CD), is among the most reported associated diseases in HS patients. Read More

View Article and Full-Text PDF

[Cutaneous lupus erythematosus].

Ugeskr Laeger 2015 Jul;177(31)

Sdr. Boulevard 59, 2. th., 5000 Odense C.

Cutaneous lupus erythematosus (LE) is an autoimmune disease. The most common clinical forms are acute cutaneous LE (ACLE), subacute cutaneous LE (SCLE) and discoid LE (DLE). Cutaneous LE, mainly ACLE, can be the first sign of systemic LE (SLE). Read More

View Article and Full-Text PDF

PSEUDOXANTHOMA ELASTICUM: DIAGNOSTIC FEATURES, CLASSIFICATION, AND TREATMENT OPTIONS.

Expert Opin Orphan Drugs 2014 Jun;2(6):567-577

PXE International, Washington, DC.

Introduction: Pseudoxanthoma elasticum (PXE), a multisystem orphan disease, clinically affects the skin, the eyes, and the cardiovascular system with considerable morbidity and mortality. The clinical manifestations reflect the underlying pathology consisting of ectopic mineralization of peripheral connective tissues.

Areas Covered: The diagnostic criteria of PXE include characteristic clinical findings, together with histopathology of accumulation of pleiomorphic elastic structures in the dermis with progressive mineralization, and the presence of mutations in the gene. Read More

View Article and Full-Text PDF

Extraintestinal manifestations of inflammatory bowel disease and the influence of smoking.

Digestion 2014 1;90(2):122-9. Epub 2014 Oct 1.

Department of Surgery, Price Institute of Surgical Research and Section of Colorectal Surgery, University of Louisville School of Medicine, Louisville, Ky., USA.

Aims: To define the number/frequency of organ systems affected by extraintestinal manifestations (EIMs), to identify factors affecting the clinical course of inflammatory bowel disease (IBD) and EIM development, and to determine the impact of smoking, disease duration and location on the diagnosis of EIMs in Crohn's disease (CD) and ulcerative colitis (UC).

Methods: IBD patients were derived from a single university colorectal surgery practice. Smoking data were obtained through a modified Behavioral Risk Factor Surveillance System survey. Read More

View Article and Full-Text PDF